Stem Cell Therapy: A Promising Treatment for COVID-19? – Technology Networks

Stem cell therapy is making its way into COVID-19 treatment. Its use seems to be particularly efficient in the case of severely ill patients, as demonstrated by a study conducted at the Beijing YouAn Hospital recently published in the peer reviewed journalAging and Disease, and as emerged after the press conference hold by Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology.Bioscience Institute a company specializing in stem cell isolation, expansion and cryopreservation reported the results of the Beijing study on the diseases associated with novel coronavirus (SARSCoV-2) infection as they were anticipated before their publication

Read more
Stem Cell Therapy Market Set to Witness an Uptick during 2017 to 2025 – Science In Me

Global Stem Cell Therapy Market: Overview Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Read more
Benefits of Stem Cells

By: Ian Murnaghan BSc (hons), MSc - Updated: 6 Apr 2020| *Discuss With all the controversy surrounding stem cells you may have missed hearing about many of the benefits for the health and medical fields. You may not even be aware that stem cells already have many applications for treating disease. Their potential to treat even more diseases in the future means that scientists are working hard to learn about how stem cells function and how they can treat some of the more serious diseases affecting the world.

Read more
MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND…

NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19). This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Healths National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-L in the treatment of patients with COVID-19 ARDS, and will provide investigational product for the trial

Read more